Clinical Use of Fluorodeoxyglucose F 18 Positron Emission Tomography for Detection of Renal Cell Carcinoma

Scott, 1994, Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F] fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group, Ann Thorac Surg, 58, 698, 10.1016/0003-4975(94)90730-7

Bailet, 1992, Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy, Laryngoscope, 102, 281, 10.1288/00005537-199203000-00010

Schiepers, 1995, Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging, Eur J Surg Oncol, 21, 517, 10.1016/S0748-7983(95)97046-0

Avril, 1996, Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose, J Natl Cancer Inst, 88, 1204, 10.1093/jnci/88.17.1204

Wahl, 1991, Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies, J Urol, 146, 1470, 10.1016/S0022-5347(17)38141-7

Ramdave, 2001, Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma, J Urol, 166, 825, 10.1016/S0022-5347(05)65845-4

Goldberg, 1997, FDG PET characterization of renal masses: preliminary experience, Clin Radiol, 52, 510, 10.1016/S0009-9260(97)80327-3

Bachor, 1996, Positron emission tomography in diagnosis of renal cell carcinoma, Urologe A, 35, 146

Miyauchi T., Brown R.S., Grossman H.B.: Correlation between visualization of primary renal cancer by FDG-PET and histopathological findings. Abstract 245. Presented at Forty-third Annual Meeting of the Society of Nuclear Medicine, Denver, Colorado, June 3–5, 1996

Miyakita, 2002, Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer, Int J Urol, 9, 15, 10.1046/j.1442-2042.2002.00416.x

Montravers, 2000, Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera, J Nucl Med, 41, 78

Montravers, 1998, In vivo inaccessibility of somatostatin receptors to 111In-pentreotide in primary renal cell carcinoma, Nucl Med Commun, 19, 953, 10.1097/00006231-199810000-00005

Jadvar H., Kherbache H.M., Conti P.S.: [F-18]-FDG PET in the evaluation of recurrent and metastatic renal cell carcinoma. Presented at annual meeting of the Academy of Molecular Imaging, San Diego, California, October 23–27, 2002

Safaei, 2002, The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer, Clin Nephrol, 57, 56, 10.5414/CNP57056

Wu, 2002, Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas—a preliminary report, J Cancer Res Clin Oncol, 128, 503, 10.1007/s00432-002-0370-1